Envista Holdings Corp (NVST) - Stock Analysis

Last updated: Apr 26, 2026

HealthcareClosed

Research Idea

Research content for general circulation. Not individualized advice. Methodology & Disclosures

Envista presents strong Q4 2025 beats, positive analyst upgrades, a raised full-year guidance, robust institutional buying, and a ~24% price gain with breakout above 21-day SMA, supported by product momentum in implants and imaging, though tariff and macro risks temper short-term certainty.

Loading chart data...

Idea window: 2/10/2026 – 2/17/2026Sector: Healthcare

AI Analyst Overview

Last Price
$26.80
Market Cap
$4.39B
1D Return
-0.89%
YTD Return
+23.45%

Loading chart data...

Valuation Metrics

P/E
93.7
P/B
1.4
P/S
1.6
EV/EBITDA
16.9
Div Yield
—

Fundamental Analysis

6.0

Key Financial Insights: • Liquidity Strength • Thin Margins • Cash Flow Support NVST has solid liquidity and strong free cash flow, but thin profit margins, high valuation, and intangible-heavy equity make the stock a cautious hold rather than an obvious buy.

MixedOutlook
Overvalued

Price Behavior

6.0

Key Price Behavior Insights: • Recovering base • Near-term resistance • Softening momentum Support Level: $25.8–$26.0 Resistance Level: $27.8–$28.0 NVST shows a modest short-term uptrend and recovering base, but it must hold $25.8–$26.0 and break above $27.8–$28.0 to confirm further upside.

uptrend
resistance

Sentiment & News

7.0

Key News Insights: • Share-price strength • Value-stock appeal • Earnings catalyst NVST's recent headlines point to strong momentum, favorable long-term fundamentals, and a positive setup ahead of its upcoming Q1 2026 earnings report.

positive
neutral
AI

AI Summary

6.0
Neutral

NVST is no longer just a cheap turnaround: recent broad-based growth, margin expansion, and higher guidance suggest real operational improvement, but the stock still deserves a discount until management proves earnings can hold up through China disruption, tariffs, and thin net margins.

Turnaround
TariffRisk
MarginExpansion
AI summary updated today

Description

Envista Holdings Corp., headquartered in Brea, California, manufactures and sells a broad range of dental products and tools and employs about 12,800 full-time staff. The company operates two reporting segments: Specialty Products & Technologies, which supplies dental implant and prosthetic systems, orthodontic products and related treatment software; and Equipment & Consumables, which provides dental office equipment, imaging and visualization systems, restorative and endodontic materials, and infection-prevention supplies. Its offerings support diagnosis, treatment and routine clinical procedures across general and specialty dental practices.

Idea History

DateCloseTickerCompanySummaryStatusP/L
Feb 10Feb 17NVSTEnvista Holdings Corp
Envista presents strong Q4 2025 beats, positive analyst upgrades, a raised full-year guidance, robust institutional buying, and a ~24% price gain with breakout above 21-day SMA, supported by product momentum in implants and imaging, though tariff and macro risks temper short-term certainty.
Closed-7.0%
Research content for educational purposes only. Not investment advice. All decisions are your responsibility.